Analysis of Biomarkers and Marginal Bone Loss in Platform-Switched and Nonplatform-Switched Implants: A Randomized Clinical Trial

Objectives. To compare the peri-implant crevicular fluid (PICF) biomarker levels, peri-implant status, and marginal bone level (MBL) differences of implants restored with randomly assigned nonplatform-switched (NPS) or platform-switched (PS) abutments. Methods. Ninety-four implants in 27 subjects we...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2022-05, Vol.2022, p.2603287-10
Main Authors: Kocak-Oztug, Necla Asli, Adem-Siyli, Gamze Zeynep, Abishev, Orkhan, Batu, Sule, Guven, Yegane, Cekici, Ali, Gokbuget, Aslan Y., Firatli, Erhan, Cintan, Serdar
Format: Article
Language:English
Subjects:
Biomarkers
Biomedical materials
Bone and Bones
Bone implants
Bone loss
Bone Remodeling
Clinical trials
Cytokines
Disease
Humans
IL-1β
Interleukins
Medical research
Monocyte chemoattractant protein 1
Monocytes
Osteoprotegerin
Patients
Surgeons
Surgery
TRANCE protein
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. To compare the peri-implant crevicular fluid (PICF) biomarker levels, peri-implant status, and marginal bone level (MBL) differences of implants restored with randomly assigned nonplatform-switched (NPS) or platform-switched (PS) abutments. Methods. Ninety-four implants in 27 subjects were included in this study. Receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG), interleukin-1β (IL-1β), monocyte chemotactic protein-1 (MCP-1) levels in PICF, peri-implant health, and the change in the MBL were evaluated at the time of restoration (T1) and after 12 months (T2). Results. The IL-1β levels decreased and the RANKL, OPG, and MCP-1 levels increased from T1 to T2 (P
ISSN:2314-6133
2314-6141
DOI:10.1155/2022/2603287